Atrial Fibrillation Monitoring on Patients With Lymphoma After Chemotherapy
NCT ID: NCT05454878
Last Updated: 2022-07-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2022-07-15
2023-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Remote Monitoring of AF Recurrence Using mHealth Technology
NCT05037136
Cardiac Monitoring of Post-Operative Cancer Patients Experiencing Atrial Fibrillation
NCT01253590
New-Onset Atrial Fibrillation Complicating Acute Myocardial Infarction in China
NCT05511649
Atrial Fibrillation in Active Cancer Patients
NCT04696081
Left Atrial Strain and Supraventricular Arrhythmia Burden in Cardiac Light Chain Amyloidosis Following Chemotherapy
NCT05448716
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Concurrent chemotherapy on patients with new-onset lymphoma: chemotherapy regimens containing anthracyclines;
3. The subject voluntarily signed the informed consent.
Exclusion Criteria
2. With Atrial fibrillation on admission
3. Patient after pacemaker surgery
4. With mental illness or mentally disabled
5. Patients that the investigator considers as unsuitable for this test
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese PLA General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yun Dai Chen
professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yundai Chen, MD
Role: PRINCIPAL_INVESTIGATOR
Chinese PLA General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
General hospital of PLA
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jingjing Wang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LAF-20220523
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.